B. Keith

发表

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

M. Berger, M. Untch, R. Finn, 2006, Cancer research.

Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.

J. Miller, J. Humphreys, T. Blumenkopf, 1999, Bioconjugate chemistry.

Distribution and metabolism of calcium leucovorin in normal and tumor tissue.

R. Mullin, B. Keith, D. Duch, 1988, Advances in experimental medicine and biology.

In vivo antitumor activity and metabolism of a series of 5-deazaacyclotetrahydrofolate (5-DACTHF) analogues.

R. Ferone, R. Mullin, B. Keith, 1992, Biochemical pharmacology.

In vivo and in vitro metabolism of 5-deazaacyclotetrahydrofolate, an acyclic tetrahydrofolate analogue.

R. Ferone, M. Hanlon, R. Mullin, 1990, Cancer research.

Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.

J. Parham, L. Frick, R. Crosby, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.

A. Waterson, R. Griffin, D. Uehling, 2009, Bioorganic & medicinal chemistry letters.

6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases

Edgar R. Wood, Robert J. Griffin, Michael J. Reno, 2008, Proceedings of the National Academy of Sciences.

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

K. Lackey, T. Gilmer, E. Wood, 2001, Molecular cancer therapeutics.

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Hong Ma, Krystal J Alligood, G. Owens, 2002, Oncogene.

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

K. Lackey, T. Gilmer, R. Crosby, 2001, Cancer research.

Breast Cancer Cells against HER-2-Overexpressing and Trastuzumab-Treated Activity of the Dual Kinase Inhibitor Lapatinib ( GW 572016 )

M. Berger, M. Untch, R. Finn, 2006 .

Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.

K. Lackey, T. Gilmer, R. Griffin, 2003, Bioorganic & medicinal chemistry letters.